)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
HBM
HBM (2142) investor relations material
HBM H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary27 Aug, 2026
Executive summary
Revenue for the six months ended 30 June 2026 was $122.5M, up 20.9% year-over-year, driven by new and expanded global licensing and collaboration agreements.
Net profit was $64.9M, down from $73.0M in 2025, reflecting higher R&D and administrative expenses.
Growth was fueled by molecule license & alliance revenue and deepened global partnerships.
The company advanced multiple clinical and preclinical programs, expanded AI-driven R&D, and achieved significant clinical and business milestones, including IND approvals and strategic partnerships.
Financial highlights
Revenue: $122.5M (up 20.9% YoY); profit: $64.9M (down $8.1M YoY).
R&D costs: $29.6M (up from $18.0M YoY); administrative expenses: $16.7M (up from $7.4M YoY).
Cash and cash equivalents: $359.2M as of 30 June 2026.
Basic and diluted EPS: $0.08 (down from $0.09 YoY).
Gross margin remained strong; cost of sales increased in line with revenue growth.
Outlook and guidance
Continued focus on advancing mid-to-late stage clinical assets and expanding global partnerships, with key data readouts and regulatory milestones expected in the next 12–24 months.
Ongoing investment in AI-driven R&D and technology platforms to accelerate innovation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from HBM
- Record 2025 revenue and profit growth fueled by innovation and global partnerships.2142
H2 2025 - Revenue up 327.5% and net profit up 51x YoY, fueled by global licensing and partnerships.2142H1 2025
- Revenue and profit declined, but major licensing and regulatory milestones were achieved.2142H1 2024
- Profitability, recurring revenue, and global partnerships drive growth outlook.2142H2 2024
Next HBM earnings date
H2 202629 Mar, 2027
HBM
Next HBM earnings date
H2 202629 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
HBM Holdings Limited is a China-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibody therapeutics. The company utilizes its proprietary antibody technology platforms to develop a pipeline of monoclonal antibodies targeting various diseases, including cancer and autoimmune disorders. HBM Holdings conducts research and clinical development independently and through strategic partnerships in both domestic and international markets. The company is headquartered in Shanghai, China, and its shares are listed on the HKEX.